医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LINNER Nova Deluxe: First Single MEMS Driver Audio Solution Powered by USound

2024年05月16日 PM04:00
このエントリーをはてなブックマークに追加


 

GRAZ, Austria

USound, the leading global provider of MEMS speakers, announced the availability of the first single MEMS driver audio solution on the market: LINNER Nova Deluxe. Designed and produced by LINNER, the notable developer of over-the-counter (OTC) hearing aids, LINNER Nova Deluxe is set to change the lives of a growing number of people affected by mild to moderate hearing loss. The advanced OTC hearing aid model has an integrated single MEMS driver from USound. Selected for their compact size and pristine sound quality, USound MEMS speakers revolutionize the audio market by enabling the production of life-changing devices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516029639/en/

A USound MEMS speaker from the Conamara series. (Photo: Business Wire)

A USound MEMS speaker from the Conamara series. (Photo: Business Wire)

“The exemplary design of LINNER Nova Deluxe, the first single MEMS driver audio solution on the market, is a monumental development in the audio industry. Witnessing the effects USound MEMS technology has on the advancements of our customers and partners, inspires us to continue our research and development efforts. At the same time, our speakers are changing the lives of millions of people around the world. People who did not have access to affordable hearing devices and who were stigmatized for their disabilities. We are proud to be part of this development and look forward to seeing our speakers revolutionize the entire audio industry!”
–Ferruccio Bottoni, USound’s CEO

MEMS-Based OTC Hearing Aids

OTC hearing aids are a new product category that caters to the increasing number of people with various levels of hearing loss, which is estimated at 1.5 billion people around the globe, according to the World Health Organization (WHO). At the same time, the market size for OTC hearing aids is valued at 1,06 billion US dollars, with a 6,60% compound annual growth rate (CARG) until 2030. MEMS speakers are the component of choice for this new product category, characterized by a small form factor and advanced audio quality, among other features.

LINNER Nova Deluxe is an advanced MEMS-powered hearing aid model, distinguished for its lightweight and discreet design and high audio quality. It is the first product on the market to utilize one single MEMS speaker, paving the way for more MEMS-powered developments.

About LINNER

LINNER is a leading OTC hearing aid company dedicated to improving the lives of individuals with hearing loss. With a focus on affordability, innovation, and exceptional quality, LINNER offers high-quality hearing aids designed to deliver clear and natural sound. Recognized by respected media outlets for their innovative and affordable solutions, LINNER ensures an optimal user experience through continuous improvements and user-focused updates. For more information, visit www.linnerlife.com

About USound

USound is a fast-growing MEMS speaker company that enables its customers to bring new revolutionary audio products to the market. USound’s unique selling proposition is based on radical miniaturization, power reduction and increased production efficiency. USound’s audio products are safeguarded by over 370 patents. Learn more by visiting www.usound.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240516029639/en/

CONTACT

Maria-Eleni Perpiraki – press@usound.com

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders